|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TNKS1BP1 |
Gene summary for TNKS1BP1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TNKS1BP1 | Gene ID | 85456 |
| Gene name | tankyrase 1 binding protein 1 | |
| Gene Alias | TAB182 | |
| Cytomap | 11q12.1 | |
| Gene Type | protein-coding | GO ID | GO:0000723 | UniProtAcc | A0A024R542 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 85456 | TNKS1BP1 | P54T-E | Human | Esophagus | ESCC | 1.42e-20 | 6.33e-01 | 0.0975 |
| 85456 | TNKS1BP1 | P57T-E | Human | Esophagus | ESCC | 1.34e-17 | 3.95e-01 | 0.0926 |
| 85456 | TNKS1BP1 | P61T-E | Human | Esophagus | ESCC | 2.42e-15 | 4.11e-01 | 0.099 |
| 85456 | TNKS1BP1 | P62T-E | Human | Esophagus | ESCC | 2.87e-29 | 7.72e-01 | 0.1302 |
| 85456 | TNKS1BP1 | P65T-E | Human | Esophagus | ESCC | 1.29e-10 | 2.89e-01 | 0.0978 |
| 85456 | TNKS1BP1 | P74T-E | Human | Esophagus | ESCC | 1.06e-15 | 4.74e-01 | 0.1479 |
| 85456 | TNKS1BP1 | P75T-E | Human | Esophagus | ESCC | 2.72e-17 | 4.26e-01 | 0.1125 |
| 85456 | TNKS1BP1 | P76T-E | Human | Esophagus | ESCC | 9.28e-07 | 1.31e-01 | 0.1207 |
| 85456 | TNKS1BP1 | P79T-E | Human | Esophagus | ESCC | 4.98e-14 | 2.85e-01 | 0.1154 |
| 85456 | TNKS1BP1 | P80T-E | Human | Esophagus | ESCC | 2.96e-12 | 7.09e-01 | 0.155 |
| 85456 | TNKS1BP1 | P82T-E | Human | Esophagus | ESCC | 2.39e-11 | 9.27e-01 | 0.1072 |
| 85456 | TNKS1BP1 | P83T-E | Human | Esophagus | ESCC | 8.13e-22 | 5.34e-01 | 0.1738 |
| 85456 | TNKS1BP1 | P84T-E | Human | Esophagus | ESCC | 1.07e-04 | 1.54e-01 | 0.0933 |
| 85456 | TNKS1BP1 | P89T-E | Human | Esophagus | ESCC | 7.88e-09 | 9.43e-01 | 0.1752 |
| 85456 | TNKS1BP1 | P91T-E | Human | Esophagus | ESCC | 1.24e-15 | 1.86e+00 | 0.1828 |
| 85456 | TNKS1BP1 | P104T-E | Human | Esophagus | ESCC | 1.03e-04 | 3.52e-01 | 0.0931 |
| 85456 | TNKS1BP1 | P107T-E | Human | Esophagus | ESCC | 1.41e-21 | 7.02e-01 | 0.171 |
| 85456 | TNKS1BP1 | P126T-E | Human | Esophagus | ESCC | 3.63e-02 | 5.99e-01 | 0.1125 |
| 85456 | TNKS1BP1 | P127T-E | Human | Esophagus | ESCC | 3.20e-14 | 1.44e-01 | 0.0826 |
| 85456 | TNKS1BP1 | P128T-E | Human | Esophagus | ESCC | 2.27e-13 | 7.60e-01 | 0.1241 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:001021217 | Esophagus | ESCC | response to ionizing radiation | 110/8552 | 148/18723 | 1.11e-12 | 4.78e-11 | 110 |
| GO:000072319 | Esophagus | ESCC | telomere maintenance | 99/8552 | 131/18723 | 2.68e-12 | 1.08e-10 | 99 |
| GO:007189716 | Esophagus | ESCC | DNA biosynthetic process | 127/8552 | 180/18723 | 1.04e-11 | 3.85e-10 | 127 |
| GO:000931419 | Esophagus | ESCC | response to radiation | 277/8552 | 456/18723 | 4.42e-11 | 1.43e-09 | 277 |
| GO:007121419 | Esophagus | ESCC | cellular response to abiotic stimulus | 206/8552 | 331/18723 | 7.52e-10 | 1.88e-08 | 206 |
| GO:010400419 | Esophagus | ESCC | cellular response to environmental stimulus | 206/8552 | 331/18723 | 7.52e-10 | 1.88e-08 | 206 |
| GO:000700418 | Esophagus | ESCC | telomere maintenance via telomerase | 56/8552 | 69/18723 | 1.40e-09 | 3.30e-08 | 56 |
| GO:007147816 | Esophagus | ESCC | cellular response to radiation | 122/8552 | 186/18723 | 3.07e-08 | 5.73e-07 | 122 |
| GO:001083319 | Esophagus | ESCC | telomere maintenance via telomere lengthening | 61/8552 | 81/18723 | 5.24e-08 | 9.37e-07 | 61 |
| GO:000627816 | Esophagus | ESCC | RNA-dependent DNA biosynthetic process | 56/8552 | 75/18723 | 3.03e-07 | 4.30e-06 | 56 |
| GO:0071479110 | Esophagus | ESCC | cellular response to ionizing radiation | 54/8552 | 72/18723 | 3.85e-07 | 5.32e-06 | 54 |
| GO:00063024 | Esophagus | ESCC | double-strand break repair | 152/8552 | 251/18723 | 1.33e-06 | 1.62e-05 | 152 |
| GO:004677710 | Esophagus | ESCC | protein autophosphorylation | 138/8552 | 227/18723 | 2.98e-06 | 3.38e-05 | 138 |
| GO:00182099 | Esophagus | ESCC | peptidyl-serine modification | 196/8552 | 338/18723 | 3.07e-06 | 3.47e-05 | 196 |
| GO:001810515 | Esophagus | ESCC | peptidyl-serine phosphorylation | 184/8552 | 315/18723 | 3.22e-06 | 3.61e-05 | 184 |
| GO:003220014 | Esophagus | ESCC | telomere organization | 99/8552 | 159/18723 | 1.77e-05 | 1.57e-04 | 99 |
| GO:00319521 | Esophagus | ESCC | regulation of protein autophosphorylation | 29/8552 | 43/18723 | 3.25e-03 | 1.35e-02 | 29 |
| GO:00331355 | Esophagus | ESCC | regulation of peptidyl-serine phosphorylation | 81/8552 | 144/18723 | 6.79e-03 | 2.48e-02 | 81 |
| GO:00319541 | Esophagus | ESCC | positive regulation of protein autophosphorylation | 19/8552 | 27/18723 | 8.35e-03 | 2.95e-02 | 19 |
| GO:001810710 | Esophagus | ESCC | peptidyl-threonine phosphorylation | 66/8552 | 116/18723 | 9.76e-03 | 3.37e-02 | 66 |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TNKS1BP1 | SNV | Missense_Mutation | c.1729N>T | p.Gly577Cys | p.G577C | Q9C0C2 | protein_coding | deleterious(0.04) | benign(0.035) | TCGA-A1-A0SO-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | SD | ||
| TNKS1BP1 | SNV | Missense_Mutation | c.1642C>G | p.Pro548Ala | p.P548A | Q9C0C2 | protein_coding | tolerated(0.1) | benign(0.04) | TCGA-A2-A1FW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD | |
| TNKS1BP1 | SNV | Missense_Mutation | novel | c.2095N>C | p.Ala699Pro | p.A699P | Q9C0C2 | protein_coding | deleterious(0.03) | possibly_damaging(0.469) | TCGA-A2-A3Y0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
| TNKS1BP1 | SNV | Missense_Mutation | rs763983688 | c.196N>T | p.Arg66Trp | p.R66W | Q9C0C2 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-A8-A095-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
| TNKS1BP1 | SNV | Missense_Mutation | c.88G>A | p.Glu30Lys | p.E30K | Q9C0C2 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| TNKS1BP1 | SNV | Missense_Mutation | novel | c.540N>A | p.Asp180Glu | p.D180E | Q9C0C2 | protein_coding | deleterious(0.04) | benign(0.323) | TCGA-AR-A0TX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TNKS1BP1 | SNV | Missense_Mutation | novel | c.41C>T | p.Ser14Phe | p.S14F | Q9C0C2 | protein_coding | deleterious(0) | probably_damaging(0.973) | TCGA-BH-A1EO-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| TNKS1BP1 | SNV | Missense_Mutation | rs774760397 | c.4129N>A | p.Gly1377Ser | p.G1377S | Q9C0C2 | protein_coding | tolerated(0.1) | benign(0.338) | TCGA-E9-A249-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
| TNKS1BP1 | insertion | Frame_Shift_Ins | novel | c.5034_5035insAAAGTTTGCATTCTGGACCTTTGCCGTCTGCCTCCTAGGT | p.Gln1679LysfsTer69 | p.Q1679Kfs*69 | Q9C0C2 | protein_coding | TCGA-A7-A0D9-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | SD | ||
| TNKS1BP1 | insertion | Frame_Shift_Ins | novel | c.5149_5150insGGCACTCACCACCACACCTGGCTAATTTTTGTATTTTTAAT | p.Asn1717ArgfsTer20 | p.N1717Rfs*20 | Q9C0C2 | protein_coding | TCGA-A8-A07G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | CR |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |